JP2023512455A - 細胞表面受容体結合化合物およびコンジュゲート - Google Patents

細胞表面受容体結合化合物およびコンジュゲート Download PDF

Info

Publication number
JP2023512455A
JP2023512455A JP2022542684A JP2022542684A JP2023512455A JP 2023512455 A JP2023512455 A JP 2023512455A JP 2022542684 A JP2022542684 A JP 2022542684A JP 2022542684 A JP2022542684 A JP 2022542684A JP 2023512455 A JP2023512455 A JP 2023512455A
Authority
JP
Japan
Prior art keywords
compound
independently
conjugate
optionally substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022542684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512455A5 (cg-RX-API-DMAC7.html
Inventor
ブレット ブラッドリー ブッシュ,
ジャスティン トーマス アーンスト,
ギャリック ケー. パッカード,
ジェイソン ジー. ルイス,
エリック ディー. タートル,
Original Assignee
ライシア セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライシア セラピューティクス, インコーポレイテッド filed Critical ライシア セラピューティクス, インコーポレイテッド
Publication of JP2023512455A publication Critical patent/JP2023512455A/ja
Publication of JP2023512455A5 publication Critical patent/JP2023512455A5/ja
Priority to JP2026019480A priority Critical patent/JP2026090375A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Primary Cells (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022542684A 2020-01-10 2021-01-08 細胞表面受容体結合化合物およびコンジュゲート Withdrawn JP2023512455A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026019480A JP2026090375A (ja) 2020-01-10 2026-02-09 細胞表面受容体結合化合物およびコンジュゲート

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062959882P 2020-01-10 2020-01-10
US202062959862P 2020-01-10 2020-01-10
US202062959877P 2020-01-10 2020-01-10
US62/959,862 2020-01-10
US62/959,882 2020-01-10
US62/959,877 2020-01-10
US202063043754P 2020-06-24 2020-06-24
US202063043749P 2020-06-24 2020-06-24
US202063043752P 2020-06-24 2020-06-24
US63/043,754 2020-06-24
US63/043,749 2020-06-24
US63/043,752 2020-06-24
PCT/US2021/012846 WO2021142377A2 (en) 2020-01-10 2021-01-08 Cell surface receptor binding compounds and conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026019480A Division JP2026090375A (ja) 2020-01-10 2026-02-09 細胞表面受容体結合化合物およびコンジュゲート

Publications (2)

Publication Number Publication Date
JP2023512455A true JP2023512455A (ja) 2023-03-27
JP2023512455A5 JP2023512455A5 (cg-RX-API-DMAC7.html) 2024-01-16

Family

ID=76788318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542684A Withdrawn JP2023512455A (ja) 2020-01-10 2021-01-08 細胞表面受容体結合化合物およびコンジュゲート
JP2026019480A Pending JP2026090375A (ja) 2020-01-10 2026-02-09 細胞表面受容体結合化合物およびコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026019480A Pending JP2026090375A (ja) 2020-01-10 2026-02-09 細胞表面受容体結合化合物およびコンジュゲート

Country Status (9)

Country Link
US (1) US20230158155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087584A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023512455A (cg-RX-API-DMAC7.html)
KR (1) KR20220144893A (cg-RX-API-DMAC7.html)
CN (1) CN115315263A (cg-RX-API-DMAC7.html)
AU (1) AU2021206280A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167272A1 (cg-RX-API-DMAC7.html)
IL (1) IL294564A (cg-RX-API-DMAC7.html)
WO (1) WO2021142377A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12697391B2 (en) 2018-04-09 2026-08-04 Yale University Bi-functional molecules to degrade circulating proteins
US12485178B2 (en) 2018-04-09 2025-12-02 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
CA3134610A1 (en) 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
US20240342293A1 (en) * 2019-10-10 2024-10-17 Yale University Engineered antibodies as molecular degraders through cellular receptors
MX2022009419A (es) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
AU2022268925A1 (en) 2021-05-03 2023-11-16 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
JP2024524614A (ja) * 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN117915956A (zh) * 2021-07-14 2024-04-19 利西亚治疗公司 M6pr细胞表面受体结合化合物和缀合物
WO2023028590A1 (en) * 2021-08-27 2023-03-02 Yale University Molecular degraders of extracellular proteins
WO2023028338A2 (en) * 2021-08-27 2023-03-02 Avilar Therapeutics, Inc. Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteins
PL4293785T3 (pl) 2021-11-12 2026-05-25 Lg Energy Solution, Ltd. Niewodny roztwór elektrolitu do litowej baterii akumulatorowej oraz litowa bateria akumulatorowa zawierająca ten roztwór
FR3132634B1 (fr) * 2022-02-15 2025-04-25 Nanomedsyn Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant
WO2024155748A1 (en) 2023-01-18 2024-07-25 Lycia Therapeutics, Inc. M6pr binding compounds and conjugates
AU2024208960A1 (en) * 2023-01-18 2025-07-24 Lycia Therapeutics, Inc. Asgpr binding compounds and conjugates
EP4651904A1 (en) * 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Lysosomal targeting bifunctional molecules for degradation of autoantibodies
FR3146400B1 (fr) * 2023-03-07 2026-01-30 Nanomedsyn Conjugués ciblant le récepteur du mannose 6-phosphate cation-indépendant et le tissu osseux
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法
CN116854754B (zh) 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
CN117924386B (zh) * 2023-12-22 2024-07-12 合肥综合性国家科学中心大健康研究院 Hpa1降解剂及其制备方法和用途
US12685782B2 (en) 2024-07-31 2026-07-21 Biohaven Therapeutics Ltd. Bifunctional degraders for the treatment of Graves' disease
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531458A (ja) * 2009-07-03 2012-12-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース6−リン酸受容体を標的とする化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US20080057072A1 (en) * 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531458A (ja) * 2009-07-03 2012-12-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース6−リン酸受容体を標的とする化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARRAGAN V. ET AL., CHEM. COMMUN., vol. pp. 85-86, JPN6025011179, 2001, ISSN: 0005702586 *
HUANG X. ET AL., BIOCONJUG CHEM, vol. 28, JPN6025011182, 2017, pages 283 - 295, ISSN: 0005552501 *

Also Published As

Publication number Publication date
AU2021206280A1 (en) 2022-08-25
IL294564A (en) 2022-09-01
JP2026090375A (ja) 2026-06-02
EP4087584A4 (en) 2024-08-28
US20230158155A1 (en) 2023-05-25
KR20220144893A (ko) 2022-10-27
WO2021142377A3 (en) 2021-10-21
WO2021142377A2 (en) 2021-07-15
CA3167272A1 (en) 2021-07-15
EP4087584A2 (en) 2022-11-16
CN115315263A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
US20230158155A1 (en) Cell Surface Receptor Binding Compounds and Conjugates
US12258332B2 (en) ASGPR cell surface receptor binding compounds and conjugates
US20240335544A1 (en) M6pr cell surface receptor binding compounds and conjugates
AU2024200822B2 (en) Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
KR102877468B1 (ko) 흔적이 없는 링커 및 이의 단백질-접합체
IL315138A (en) Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
CN112004557A (zh) 类固醇类化合物及其抗体偶联物
KR20170117473A (ko) 리간드-세포독성 약물 접합체, 이의 제조 방법 및 이의 적용
CN120456929A (zh) Cd70抗体药物缀合物及其使用方法
CN120267848A (zh) 一种抗体偶联药物及其用途
EP4651902A2 (en) Asgpr binding compounds and conjugates
EP4651903A1 (en) M6pr binding compounds and conjugates
AU2023407365A1 (en) Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
EA046545B1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260218

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260312